These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38889738)

  • 1. Hepatitis C virus diversity and treatment outcomes in Benin: a prospective cohort study.
    Ahovègbé L; Shah R; Kpossou AR; Davis C; Niebel M; Filipe A; Goldstein E; Alassan KS; Keke R; Sehonou J; Kodjoh N; Gbedo SE; Ray S; Wilkie C; Vattipally S; Tong L; Kamba PF; Gbenoudon SJ; Gunson R; Ogwang P; Thomson EC
    Lancet Microbe; 2024 Jul; 5(7):697-706. PubMed ID: 38889738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
    Lacombe K; Moh R; Chazallon C; Lemoine M; Sylla B; Fadiga F; Le Carrou J; Marcellin F; Kouanfack C; Ciaffi L; Sartre MT; Sida MB; Diallo A; Gozlan J; Seydi M; Cissé V; Danel C; Girard PM; Toni TD; Minga A; Boyer S; Carrieri P; Attia A;
    Sci Rep; 2024 May; 14(1):10244. PubMed ID: 38702350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
    Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.
    Kateera F; Shumbusho F; Manirambona L; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Kabakambira JD; Sylvain H; Camus G; Grant PM; Gupta N
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):533-541. PubMed ID: 35248213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
    Gupta N; Manirambona L; Shumbusho F; Kabihizi J; Murangwa A; Serumondo J; Makuza JD; Nsanzimana S; Muvunyi CM; Mukabatsinda C; Musabeyezu E; Camus G; Grant PM; Kateera F
    Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):542-551. PubMed ID: 35248212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population.
    Kouris G; Hydery T; Greenwood BC; Lavitas P; Price M; Clements K; Alper CJ; Lenz K; Jeffrey PL
    J Manag Care Spec Pharm; 2018 Jul; 24(7):591-597. PubMed ID: 29952708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.
    Lawitz E; Landis CS; Flamm SL; Bonacini M; Ortiz-Lasanta G; Huang J; Zhang J; Kirby BJ; De-Oertel S; Hyland RH; Osinusi AO; Brainard DM; Robson R; Maliakkal BJ; Gordon SC; Gane EJ
    Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):918-926. PubMed ID: 32531259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
    Hu C; Yuan G; Liu J; Huang H; Ren Y; Li Y; Chen X; Li W; Wu T; Deng H; Peng Y; Zhang YY; Zhou Y
    Can J Gastroenterol Hepatol; 2018; 2018():3908767. PubMed ID: 30538973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Gayam V; Tiongson B; Khalid M; Mandal AK; Mukhtar O; Gill A; Garlapati P; Shrestha B; Khalid M; Chakraborty S; Guss D; Sherigar J; Mansour M; Mohanty S
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1200-1207. PubMed ID: 30096090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
    Curry MP; O'Leary JG; Bzowej N; Muir AJ; Korenblat KM; Fenkel JM; Reddy KR; Lawitz E; Flamm SL; Schiano T; Teperman L; Fontana R; Schiff E; Fried M; Doehle B; An D; McNally J; Osinusi A; Brainard DM; McHutchison JG; Brown RS; Charlton M;
    N Engl J Med; 2015 Dec; 373(27):2618-28. PubMed ID: 26569658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    Ueda Y; Ikegami T; Akamatsu N; Soyama A; Shinoda M; Goto R; Okajima H; Yoshizumi T; Taketomi A; Kitagawa Y; Eguchi S; Kokudo N; Uemoto S; Maehara Y
    J Gastroenterol; 2017 Aug; 52(8):986-991. PubMed ID: 28138756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
    Townshend-Bulson L; Roik E; Barbour Y; Bruden DJT; Homan CE; Espera HGF; Stevenson TJ; Hewitt AM; Rhodes W; Gove JE; Plotnik JN; Snowball MM; McGilvray J; Simons BC; Johnston JM; McMahon BJ
    PLoS One; 2021; 16(12):e0260970. PubMed ID: 34855920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.
    Gupta N; Mbituyumuremyi A; Kabahizi J; Ntaganda F; Muvunyi CM; Shumbusho F; Musabeyezu E; Mukabatsinda C; Ntirenganya C; Van Nuil JI; Kateera F; Camus G; Damascene MJ; Nsanzimana S; Mukherjee J; Grant PM
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):119-126. PubMed ID: 30552056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
    Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.